Skip to main content

MEDP

Stock
Health Care
Diagnostics & Research

Performance overview

MEDP Price
Price Chart

Forward-looking statistics

Beta
1.22
Risk
39.69%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees6K
Market cap$12.4B

Fundamentals

Enterprise value$8.7B
Revenue$2.2B
Revenue per employee—
Profit margin19.31%
Debt to equity25.33

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$13.09
Dividend per share—
Revenue per share$69.92
Avg trading volume (30 day)$119M
Avg trading volume (10 day)$143M
Put-call ratio—

Macro factor sensitivity

Growth+8.6
Credit-15.9
Liquidity+0.9
Inflation+7.4
Commodities+3.8
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio25.74
Price to sales4.28
P/E Ratio25.74
Enterprise Value to Revenue4.05
Price to book16.12

Upcoming events

Next earnings dayApril 22, 2025
Next dividend day—
Ex. dividend day—

News

Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider

In the closing of the recent trading day, Medpace (MEDP) stood at $328.24, denoting a +2.27% move from the preceding trading day.

Zacks Investment Research (July 10, 2025)
Why Is Medpace Stock Diving On Tuesday?

Medpace Holdings, Inc. MEDP shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.

Benzinga (October 22, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free